The results showed that PD-L1 expression increased in these immune cells after alisertib treatment, and the intensity of PD-L1 was much higher in macrophages, MDSCs, and DCs than in tumor cells (Supplemental Figure 7B). This evidence concerns the gene CD274 and neoplasm.